Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HOLX 
Hologic Inc (HOLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: HOLX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -25.79% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.67B USD | Price to earnings Ratio 19.16 | 1Y Target Price 78.15 |
Price to earnings Ratio 19.16 | 1Y Target Price 78.15 | ||
Volume (30-day avg) 2357146 | Beta 0.97 | 52 Weeks Range 60.03 - 84.67 | Updated Date 04/2/2025 |
52 Weeks Range 60.03 - 84.67 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 18.42% | Operating Margin (TTM) 22.87% |
Management Effectiveness
Return on Assets (TTM) 7.1% | Return on Equity (TTM) 15.78% |
Valuation
Trailing PE 19.16 | Forward PE 14.47 | Enterprise Value 14340734384 | Price to Sales(TTM) 3.38 |
Enterprise Value 14340734384 | Price to Sales(TTM) 3.38 | ||
Enterprise Value to Revenue 3.55 | Enterprise Value to EBITDA 10.68 | Shares Outstanding 225723008 | Shares Floating 222275862 |
Shares Outstanding 225723008 | Shares Floating 222275862 | ||
Percent Insiders 0.85 | Percent Institutions 105.08 |
Analyst Ratings
Rating 3.67 | Target Price 85.44 | Buy 4 | Strong Buy 5 |
Buy 4 | Strong Buy 5 | ||
Hold 12 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Hologic Inc
Company Overview
History and Background
Hologic Inc. was founded in 1985. Initially focused on bone densitometry, it expanded through acquisitions and internal development to become a leader in women's health. Key milestones include acquiring Cytyc Corporation in 2007 and Gen-Probe in 2012.
Core Business Areas
- Diagnostics: Develops and manufactures molecular diagnostic products for infectious diseases, including women's health, virology, and blood screening. Includes COVID-19 testing.
- Breast Health: Provides mammography and breast biopsy products and services. Includes digital mammography systems, breast tomosynthesis, and related accessories.
- Surgical: Offers gynecological surgical products, including NovaSure endometrial ablation and MyoSure hysteroscopic tissue removal systems.
- GYN Surgical Solutions: Minimally invasive solutions that address women's healthcare needs through its NovaSure and MyoSure offerings.
Leadership and Structure
As of 2024, the CEO is Stephen P. MacMillan. Hologic has a typical corporate structure with functional departments like R&D, Sales, Marketing, and Finance, led by senior vice presidents.
Top Products and Market Share
Key Offerings
- Market Share (%):
- Panther System: A fully automated, integrated molecular diagnostic platform. This system automates all steps from sample to result. Competitors include Roche, Abbott, and Siemens Healthineers. Revenue is significant, but not separately reported.
- Genius 3D Mammography: A breast tomosynthesis system for early breast cancer detection. Market share leader in 3D mammography in the US. Competitors include GE Healthcare and Siemens Healthineers. Specific revenue numbers are not disclosed.
- Market Share (%):
- Market Share (%):
- NovaSure Endometrial Ablation System: A minimally invasive procedure to treat heavy menstrual bleeding. Competitors include Boston Scientific and Medtronic. Specific revenue numbers are not disclosed.
Market Dynamics
Industry Overview
The diagnostics and medical devices industry is driven by technological advancements, aging populations, and increasing healthcare spending. Focus on early detection and minimally invasive procedures is increasing.
Positioning
Hologic holds a strong position in women's health, especially in breast health and diagnostics. Their competitive advantage lies in their innovative technology and strong market presence.
Total Addressable Market (TAM)
The TAM for Hologic's core markets (diagnostics, breast health, and surgical) is estimated to be in the tens of billions of dollars. Hologic is well-positioned to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Strong market position in women's health
- Innovative technology
- Established brand reputation
- Diversified product portfolio
- Recurring revenue streams from diagnostics
Weaknesses
- Reliance on a few key products
- Exposure to reimbursement pressures
- Dependence on acquisitions for growth
- Potential for product liability claims
Opportunities
- Expanding into emerging markets
- Developing new diagnostic tests
- Acquiring complementary businesses
- Leveraging digital health solutions
- Partnerships with hospitals
Threats
- Increased competition
- Changing healthcare regulations
- Economic downturn
- Technological obsolescence
- Patent expirations
Competitors and Market Share
Key Competitors
- ABT
- RHHBY
- SIEMENS
Competitive Landscape
Hologic faces intense competition in the diagnostics and medical device industries. Its competitive advantage lies in its focus on women's health and its innovative products. Maintaining this focus will be essential for continued success.
Major Acquisitions
Biotheranostics
- Year: 2021
- Acquisition Price (USD millions): 230
- Strategic Rationale: Expanded Hologicu2019s oncology testing capabilities.
Somatex Medical Technologies GmbH
- Year: 2021
- Acquisition Price (USD millions): 64
- Strategic Rationale: Strengthened Hologic's breast health portfolio with innovative biopsy site markers.
Growth Trajectory and Initiatives
Historical Growth: Hologic has historically grown through acquisitions and organic growth, driven by the demand for its women's health products. However, growth can be erratic due to external factors.
Future Projections: Analyst estimates project continued growth for Hologic, driven by new product launches and expansion into emerging markets. Growth varies based on acquisitions, market acceptance, and competition.
Recent Initiatives: Recent strategic initiatives include investment in research and development, new product launches and targeted acquisitions.
Summary
Hologic is a relatively strong player in the women's health market, particularly in breast health and diagnostics. Its innovative products and established brand reputation are working well, but the company faces threats from increased competition and reimbursement pressures. Hologic needs to continue investing in research and development and expanding into new markets to sustain its growth. Strategic acquisitions may be needed to remain competitive.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- Hologic Investor Relations
- Company SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hologic Inc
Exchange NASDAQ | Headquaters Marlborough, MA, United States | ||
IPO Launch date 1990-06-21 | CEO - | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 7063 | Website https://www.hologic.com |
Full time employees 7063 | Website https://www.hologic.com | ||
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.